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Abstract
Background: Hotspot mutations of the oncogenes BRAF and NRAS are the most common genetic alterations in
cutaneous melanoma. Specific inhibitors of BRAF and MEK have shown significant survival benefits in large phase III
trials. However, the prognostic significance of BRAF and NRAS mutations outside of clinical trials remains unclear.
Methods: The mutational status of BRAF (exon 15) and NRAS (exon 2 and 3) was determined in melanoma samples of
217 patients with pyrosequencing and Sanger sequencing. The genotypes were correlated with clinical outcomes and
pathologic features of the primary tumors. Time to disease progression was calculated with the cumulative incidence
function. Survival analyses were performed with Kaplan-Meier estimates and Cox proportional hazards regression
analysis. Relative survival was calculated with the Ederer-II method. Treatment with BRAF and MEK inhibitors and
immune checkpoint blockade (ICB) was allowed.
Results: Mutations in BRAF and NRAS were identified in 40.1 and 24.4% of cases, respectively. Concurrent mutations in
both genes were detected in further 2.3%. The remaining 33.2% were wild type for the investigated exons (WT). BRAF
mutations were significantly associated with younger age at first diagnosis (p < 0.001) and truncal localization of the
culprit primary (p = 0.002). The nodular subtype was most common in the NRAS cohort. In addition, NRAS-mutant
melanoma patients showed a higher frequency of nodal relapse (p = 0.013) and development of metastatic disease
(p = 0.021). The time to loco-regional nodal relapse was shortest in NRAS-mutant melanoma (p = 0.002). Presence
of NRAS mutation was an independent risk factor for disease progression in multivariate analysis (HR 2.01; 95% CI
1.02 – 3.98). BRAF-mutant melanoma patients showed a tendency for better overall and relative survival. Genotype
was not a consistent risk factor in multivariate analysis. Instead, positive sentinel lymph node status (HR 2.65; 95% CI
1.15 – 6.10) and treatment with ICB in stage IV disease (HR 0.17; 95% CI 0.06–0.48) were significant multivariate risk
factors.
Conclusions: NRAS-mutant tumors tended to behave more aggressively particularly in early stages of the disease in
this high-risk melanoma population. Treatment with immune checkpoint blockade improved survival in stage IV disease
in a real-world setting.
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Background
Melanoma is a malignancy originating from melanocytes
of the skin with a high propensity to metastasize. Acti-
vating mutations of the oncogenes BRAF and NRAS lead
to constitutive signaling of the mitogen-activated protein
kinase (MAPK) pathway and thereby enhance tumor
growth and promote disease progression [1, 2]. Genetic
alterations in both genes can be detected in approximately
40 and 20% of cases, respectively [1]. Although specific
tyrosine kinase inhibitors targeting BRAF (BRAFi) and
MEK (MEKi) are currently available for metastatic me-
lanoma, the overall biologic and prognostic significance of
BRAF and NRAS mutations remains unclear and con-
flicting evidence exists.
In melanoma, the most common mutation of BRAF is
a substitution from valine (V) to glutamic acid (E) in
codon 600 of exon 15 (V600E). This particular alteration
was previously associated with younger age at initial
diagnosis, little chronic UV damage, truncal localization
of the primary tumor, and a high total body nevus count
[3–7]. Nevertheless, the significance for the further
course of the disease such as distant metastasis-free or
overall survival (OS) is less clear. One study proposed
that mutant BRAF had no impact on the disease-free
interval from diagnosis of the culprit tumor to first dis-
tant metastasis. However, the median survival in stage
IV disease was shorter in patients with BRAF-mutant
melanoma and not treated with a BRAF inhibitor than
in the wild type (WT) situation [8, 9]. These findings are
opposed to other analyses in which patients not treated
with BRAF inhibition showed similar survival curves to
WT patients [10, 11].
The NRAS gene is most frequently mutated at hot-
spots in exon 2 (codons 12 and 13) and exon 3 (codon
61) [12]. Mutations of NRAS were previously associated
with nodular subtype of the primary tumor and
localization in sun-damaged skin [13]. As is the case for
BRAF, studies investigating the prognostic relevance of
NRAS have revealed discordant results. One of the first
examinations dealing with this question identified NRAS
as an independent factor indicative of favorable OS [14].
Others have found that NRAS mutation status predicted
shorter survival after the diagnosis of stage IV disease
[12, 15]. In contrast, no differences in OS after diagnosis
of distant metastases were detected in several other in-
vestigations [11, 16–18].
To further elucidate the prognostic impact of muta-
tions in the BRAF and NRAS genes, we analyzed the
genotype of 217 patients with melanoma and retrospec-
tively correlated the mutation status to primary tumor
and clinical data. To account for a real-life situation and
respect potential survival benefits achieved with novel
therapy options, patients receiving targeted therapy with
kinase inhibitors and immune checkpoint blockade
(ICB) with ipilimumab, nivolumab, or pembrolizumab
were included in our analysis.
Methods
Study cohort and data collection
A total of 217 melanoma patients with available infor-
mation on the mutational status of the oncogenes
BRAF and NRAS were included. Clinical and histologic
data were retrieved retrospectively from the routine pa-
tient records of the dermato-oncology unit of the Uni-
versity Hospital of Munich (LMU) and from the
Munich Cancer Registry database (MCR). The MCR is
a population-based prospective cancer registry with stan-
dardized case report forms for patient characteristics,
TNM stage, therapy, follow-up, disease progression, and
vital status [19–22].
Cases with in situ melanoma, lentigo maligna, un-
known primaries and uveal melanoma were excluded.
All patients were classified according to the cutaneous
melanoma staging guidelines of the American Joint
Committee on Cancer (AJCC) as stated in 2009 [23].
The data were merged to a central database prior to stat-
istical analyses and comprised: demographics, perfor-
mance and result of sentinel lymph node biopsy (SLNB),
TNM stage, AJCC stage, therapies, and coincidence of
other malignancies. The primary tumor information was
ascertained by the original pathology report and provided
information on tumor site, histologic type, Breslow’s
depth, Clark’s level, ulceration, and mitotic activity. Mi-
totic activity was determined by the presence of ≥ 1 mi-
totic figure. If multiple primary melanomas were present
in one patient, the tumor which was considered respon-
sible for disease progression (culprit tumor) was deter-
mined with a previously described algorithm [11, 24, 25].
Tumor samples and mutation analyses
Mutations were tested preferentially in distant or lymph
node metastases as heterogeneity of the mutational sta-
tus between metastatic and primary tumor sites have
been reported and as BRAF mutations have predictive
value for the use of BRAFi and MEKi in metastatic dis-
ease [26, 27]. If no such samples were available, analyses
were performed in primaries. Areas of tumor tissue were
identified from 10 μm-thick formalin-fixed, paraffin-
embedded sections. To enrich for a content of > 75%, tu-
mors were manually micro-dissected with an ultra-thin
cannula. DNA was isolated with extraction buffer (Tris-
HCl pH 7.4 0.1 M, EDTA 0.5 mM, Tween 20 0.5% in
distilled water) after proteinase K hydrolysis for 16 h
(Thermo Fisher Scientific, Darmstadt, Germany). Sam-
ples were amplified using polymerase chain reactions
(PCR) covering BRAF exon 15 (Codon 600), NRAS exon
2 (codon 12, 13), and NRAS exon 3 (codon 61) using
specific primers (Additional file 1: Tables S1 and S2).
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PCR products were subsequently subjected to pyrose-
quencing with the PyroMark Q24 System (Qiagen,
Hilden, Germany) together with specific primers
(Additional file 1: Table S2). If sequencing results
were unclear or if mutations were detected in both
genes, pyrosequencing was followed by additional
Sanger sequencing to confirm the mutational status
which was performed by MWG Operon (Ebersberg,
Germany).
Endpoints
During follow-up, we defined three distinct types of disease
progression: (i) local recurrence, (ii) regional lymph node
metastasis or lymph node recurrence for patients who
initially presented with nodal disease, and (iii) formation of
distant metastasis. For the purpose of analysis, patients
were allowed to have more than one type of progression, if
the progression events developed successively and if they
were evident in timely distinct staging procedures (i.e.,
lymph node relapse followed by metastatic disease). If more
than one progression type occurred at the same time, the
event of higher prognostic value was used for the analysis
(distant metastasis > lymph node metastasis > local
recurrence).
Time to progression (TTP) was determined as time
from melanoma diagnosis to first disease progression
and documented separately for each type of progres-
sion. For time to event analyses, local recurrence and
regional lymph node metastasis were analyzed as joint
category due to the low lumber of local relapses (loco-
regional). OS was defined as the time from the initial
diagnosis of melanoma to disease-specific death or to
the date of the last documented contact which was used
as censored observation. Post-progression survival
(PPS) started after the first disease progression and was
recorded until death due to any cause occurred. The
vital status was recorded and updated regularly by the
treating oncologists and validated by death certificates
issued by municipal registration offices.
Statistical analyses
Before inferential analyses were performed, data were
analyzed with descriptive measures for central tenden-
cies and variation. Frequency distribution tables were
generated for each parameter of interest. Associations
with mutation types were analyzed for the three ge-
notypes BRAF-mutant, NRAS-mutant, and WT for
both genes. Chi-square and Kruskal-Wallis tests were
applied to assess differences of categorical and ordinal
data, respectively.
TTP was calculated with the cumulative incidence
function according to Kalbfleisch and Prentice in which
death was considered a competing risk. The respective
curves were compared for significance with the Gray’s
test. OS and PPS were computed with the product limit
(Kaplan-Meier) method for censored failure time data
assuming proportional hazards. Survival curves were
compared with the log-rank test. Relative survival (RS)
was defined as ratio of the observed to expected sur-
vival of a matched melanoma-free population and cal-
culated with the Ederer-II method. Thus, the relative
survival represented an accurate and objective estimate
of tumor-specific survival (net melanoma survival) and
was adjusted for age-dependent mortality [28].
Univariate hazard ratios (HR), 95% confidence inter-
vals (95% CI), and p-values for OS were obtained with
Cox proportional hazard regression modelling. Associ-
ations between independent covariates and OS were
calculated with multivariate Cox regression. Associa-
tions between risk factors of interest and TTP were
assessed in a multivariate risk model where death was
considered a competing risk. The reference parameters
for Cox regression and competing risk models were
age < 50 years, male sex, Breslow’s thickness < 1.00 mm,
negative nodal status, WT for BRAF and NRAS, non-
nodular subtype, and no systemic therapy. Two-sided p-
values were calculated in all cases. The significance level
for contingency tables was adjusted for multiple hypo-
thesis testing by a family-wise Bonferroni correction, test-
ing each individual hypothesis at a significance level of
p = 0.05/m with m being the number of comparisons
made in the respective table. All analyses were per-
formed with SAS programming package version 9.1
(SAS Institute Inc., Cary, NC, USA).
Results
Mutation frequencies of BRAF and NRAS
A total of 217 patients with available information on their
BRAF and NRAS genotype status were included. Muta-
tions in either one gene were detected in tumors from 140
patients (64.5%). BRAF but not NRAS was mutated in 87
cases (40.1%), while 53 patients (24.4%) showed NRAS
mutations. Genetic alterations in both genes were present
in 5 patients (2.3%). Seventy-two patients (33.2%) showed
no mutation in BRAF exon 15 or NRAS exon 2 or 3. They
were further referred to as WT. The mutation status was
assessed in two or more melanoma lesions in 23 pa-
tients (10.6%) with concordant genotypes in all cases.
Of patients with BRAF mutations, 63 (72.4%) dis-
played V600E, 15 (17.2%) V600K, and 4 (4.6%) V600R
mutations. Non-V600 mutations of BRAF were present
in 5 cases (2.3%). Of patients with NRAS mutations,
the majority showed alterations for glutamine at pos-
ition 61 with Q61K (n = 22, 41.5%) or Q61R (n = 19,
8.8%) being the most common substitutions. Concur-
rent mutations of BRAF and NRAS were identified in 5
patients (2.3%), two of whom showed non-V600 muta-
tions in the BRAF gene (Table 1).
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Associations with clinical features, characteristics of
the primary culprit tumor, and progression and survival
data were assessed based on the mutation status of
BRAF and NRAS, revealing the three cohorts BRAF-
mutant, NRAS-mutant and WT. Because of the small
number (n = 5) and the unclear significance of concur-
rent BRAF and NRAS mutations, this group was pre-
cluded from further analysis.
Clinical and pathologic features at primary diagnosis
The diagnoses of the culprit tumors were made between
1970 and 2014. Patients with BRAF-mutant melanoma
were significantly younger than those with NRAS muta-
tions or WT patients (median 56 versus 66 and 67 years,
respectively; p < 0.001). Based on the original pathology
reports, all patients were staged according to the staging
system of the AJCC from 2009 [23]. Most (95.9%)
patients presented with local or nodal disease with no
major differences of the initial disease stage between the
genotypes (Table 2). Eight patients (4.2%) were diagnosed
with metastatic (stage IV) disease. Coincident malignan-
cies were significantly more common in NRAS-mutant,
but not in BRAF-mutant nor WT patients (p = 0.003).
The mutation status was strongly associated with the
anatomic site of the culprit tumor. Six patients (2.9%)
had melanoma of mucosal origin. Among patients who
had a cutaneous primary, trunk was the most frequent
localization in the BRAF- and NRAS-mutant cohorts
(45.9% and 38.0%, respectively; p = 0.002). The localization
was more evenly distributed in the WT group with no
obvious predilection sites (Table 3). Nodular melanoma
(NM) was the most frequent histologic type in the entire
population (n = 85, 41.1%). The highest portion of the
aggressive NM subtype was observed in NRAS-mutant
patients (52.0%). Although the acral lentiginous type was
rarely detected, it appeared more common in the WT
than in the mutant cohorts (15.3 versus 3.4% for BRAF
and 4.0% for NRAS). There were no significant differences
between the three cohorts with respect to Breslow’s depth,
Clark’s level, or ulceration of the primary tumor. Likewise,
there was no significant association of the T status with
the genotype. Mitotic activity was more commonly found
in primary tumors of NRAS-mutant and WT patients
than in those with BRAF mutations (p = 0.002).
Patterns of disease progression
The overall relapse rate (patients with at least one type
of recurrence) was 85.8%. Local relapse at the primary
tumor site was rare and observed in only 6 patients
(2.8%), 4 of whom showed NRAS mutations (Table 4). A
relapse of loco-regional nodal disease was observed in
92 patients (43.3%). The formation of distant metastases
was detected in 157 patients (77.0%) during the course
of the disease. Notably, relapse of nodal disease was sig-
nificantly more common in the NRAS-mutant cohort
than in WT or BRAF-mutant patients, suggesting that
this subgroup was at highest risk for disease progression
(p = 0.013).
The median time to first disease progression of any
type was 2 years (IQR 0.8 – 5.1) for the entire popula-
tion. According to mutational status, the median TTP
was shortest in the NRAS-mutant group (1.5 years, IQR
0.7 – 4.9) and longest for patients whose tumors har-
bored BRAF mutations (2.4 years, IQR 1 – 7.5). WT pa-
tients showed a median TTP of 1.7 years (IQR 0.9 – 3.6;
p = 0.0749) (Fig. 1a). The median time to loco-regional
relapse was shortest in the NRAS group (3.3 years), a
finding with high statistical significance (p = 0.0016). In
contrast, it was not reached by patients who were mu-
tant for BRAF during the observation period (Fig. 1b). In
line with these results, the median time from primary
diagnosis of the culprit tumor to the detection of distant
metastasis was 2.6 and 2.9 years for the WT and NRAS
group, respectively, as opposed to 4.1 years in the BRAF
Table 1 Frequencies and types of BRAF and NRAS mutations
Mutation Number of patients (n, %) % of subpopulation
BRAF 87 (40.1) BRAF (n = 87)
V600E 63 (29.0) 72.4
V600K 15 (6.9) 17.2
V600R 4 (1.8) 4.6
K601E 2 (0.9) 2.3
L597S 1 (0.5) 1.1
V600E, K601E 1 (0.5) 1.1
A598A, R603* 1 (0.5) 1.1
NRAS 53 (24.4) NRAS (n = 53)
Q61K 22 (10.1) 41.5
Q61R 19 (8.8) 35.8
Q61L 3 (1.4) 5.7
Q61V 1 (0.5) 1.9
Q61H 1 (0.5) 1.9
A59D 2 (0.9) 3.8
G12D 1 (0.5) 1.9
G13R 2 (0.9) 3.8
BRAF + NRAS 5 (2.3) BRAF + NRAS (n = 5)
V600E, Q61K 1 (0.5) 20.0
V600E, Q61L 1 (0.5) 20.0
V600E, G12S 1 (0.5) 20.0
K601E, Q61L 1 (0.5) 20.0
L584F, Q61K 1 (0.5) 20.0
Mutation frequencies of BRAF (exon 15) and NRAS (exon 2 and 3) are indicated in
total numbers (n) and percentages (%). The codons which are affected by the
genetic alterations (left column) are indicated by Arabic numbers. The amino
acids are indicated by single letter codes with terminator/end codes indicated by
an asterisk (*)
Heppt et al. BMC Cancer  (2017) 17:536 Page 4 of 12
cohort (Fig. 1c; p = 0.0730). Similar results were ob-
tained when patients with relapse only were selected
for TTP analyses (Fig. 1b+c, right panels). Furthermore,
NRAS mutational status was an independent risk factor
for disease progression in a multivariate risk model
where death was considered a competing risk (HR for
progression 2.01; 95% CI 1.02 – 3.98; Table 5).
Post-progression survival
The median survival after disease progression was
3.4 years for the entire population (IQR 1.9 – 7.9).
Survival time after any disease progression did not
show significant differences between all three cohorts
(p = 0.9413) (Fig. 2a). Median survival after nodal re-
lapse was 5.2 years (IQR 2.3-not reached) and did not
show a significant association with genotype (p =
0.7945) (Fig. 2b). The median survival in stage IV was
2.1 years (IQR 1.1 – 4.5). Patients who were mutant
for NRAS showed the shortest median survival after
distant metastases were detected, although this trend
was not significant (NRAS 1.8 years, BRAF 2.2 years,
WT 2.5 years; p = 0.2474).
Table 2 Clinical characteristics at primary diagnosis of the culprit tumor
BRAF n = 87 (100.0) NRAS n = 53 (100.0) Wild type n = 72 (100.0) Total n = 212a (100.0) p-value
Gender
Male 44 (50.6) 29 (54.7) 30 (41.7) 103 (48.6) 0.314
Female 43 (49.4) 24 (45.3) 42 (58.3) 109 (51.4)
Age
median (years) 56 66 67 64 0.001*
IQR (years) 44 – 67 54.5 – 76 59 – 75 50 – 72
< 50 31 (35.6) 9 (17.0) 12 (16.7) 52 (24.5) 0.001*
50 – 59 19 (21.8) 10 (18.9) 6 (8.3) 35 (16.5)
60 – 69 22 (25.3) 13 (24.5) 20 (27.8) 55 (25.9)
≥ 70 15 (17.2) 21 (39.6) 34 (47.2) 70 (47.2)
SLNBb
not performed 42 (48.3) 24 (45.3) 24 (33.3) 90 (43.9) 0.077
performed 41 (49.4) 26 (52.0) 48 (66.7) 115 (56.1)
SLN positive 23 (26.4) 14 (26.4) 20 (27.8) 57 (26.9) 0.352
SLN negative 18 (20.7) 12 (22.6) 28 (38.9) 58 (27.4)
AJCC stagec
I 27 (35.5) 14 (29.2) 14 (21.2) 55 (29.0) 0.199
II 18 (23.7) 16 (33.3) 29 (43.9) 63 (33.2)
III 29 (38.2) 15 (31.3) 20 (30.3) 64 (33.7)
IV 2 (2.6) 3 (6.3) 3 (4.6) 8 (4.2)
N status (TNM)d
N0 46 (60.5) 31 (64.6) 43 (64.2) 120 (62.8) 0.980
N1 15 (19.7) 10 (20.8) 14 (20.9) 39 (20.4)
N2 9 (11.8) 4 (8.3) 7 (10.5) 20 (10.5)
N3 6 (7.9) 3 (6.3) 3 (4.5) 12 (6.3)
M status (TNM)
M0 85 (97.7) 50 (94.3) 69 (95.8) 204 (96.2) 0.585
M1 2 (2.3) 3 (5.7) 3 (4.2) 8 (3.8)
Other malignanciese
no 75 (91.5) 35 (68.6) 57 (82.6) 167 (82.7) 0.003*
yes 7 (8.5) 16 (31.4) 12 (17.4) 35 (17.3)
Baseline demographic and clinical characteristics are indicated according to genotype. Categorical variables were compared with the Chi-square test and age
differences with the non-parametric Kruskal-Wallis test; the significance level was adjusted with the Bonferroni correction with p < 0.006 considered significant (*).
aFive patients showed mutations in both BRAF and NRAS; bno data on SLNB performance available for n = 7; cno definite AJCC staging available for n = 22; dunknown N
status for n = 21; eno information for other malignancies available for n = 10; SLNB sentinel lymph node biopsy, IQR interquartile range, AJCC American Joint Committee
on Cancer
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Thirty-two patients of the entire cohort (14.7%) re-
ceived targeted therapy with BRAFi or MEKi, 39 (18.0%)
received ICB with ipilimumab, pembrolizumab, or nivo-
lumab and 31 (14.3%) investigator-choice chemother-
apy. The median survival time of ICB-treated patients
was not reached, while it was estimated as 2.1 years
for targeted therapy and 1.9 years for chemotherapy.
The Kaplan-Meier curves of patients treated with ICB
were superior over those treated with targeted therapy
or chemotherapy, but this difference was not signifi-
cant (p = 0.0805).
Overall and relative survival
Median survival time from primary diagnosis to death
(OS) was 11.9 years for the entire collective (IQR 4.1-
not reached). The median follow-up times were 4.2 years
(IQR 1.7 – 6.9) for the BRAF cohort and 3.9 years (IQR
1.5 – 7.1) for the NRAS cohort. WT patients had a
shorter follow-up time of 2.8 years (IQR 1.2 – 4.2). To
internally validate the dataset, OS was analyzed accord-
ing to disease stage at primary presentation. Survival
curves showed a significant difference from stages I to
IV (Additional file 2: Figure S1; p = 0.0045). According
Table 3 Primary tumor characteristics of the cohorts according to genotype
BRAF n = 87 (100.0) NRAS n = 53 (100.0) Wild type n = 72 (100.0) Total n = 212a (100.0) p-value
Localization
Acral 3 (3.5) 4 (8.0) 14 (19.4) 21 (10.1) 0.002*
Head / neck 14 (16.5) 5 (10.0) 15 (20.8) 34 (16.4)
Arms 7 (8.2) 10 (20.0) 10 (13.9) 27 (13.0)
Trunk 39 (45.9) 19 (38.0) 15 (20.8) 73 (35.3)
Legs 22 (25.9) 10 (20.0) 14 (19.4) 46 (22.2)
Mucosal 0 (0.0) 2 (4.0) 4 (5.6) 6 (2.9)
Histologic subtypea
ALM 3 (3.53) 2 (4.0) 11 (15.3) 16 (7.7) 0.021
LMM 2 (2.35) 0 (0.0) 2 (2.78) 4 (1.93)
NM 32 (37.7) 26 (52.0) 27 (37.5) 85 (41.1)
SSM 37 (43.5) 14 (28.0) 17 (23.6) 68 (32.9)
unclassified 11 (12.9) 8 (16.0) 15 (20.8) 34 (16.4)
Breslow’s indexb
≤ 1.00 mm 43 (50.6) 26 (52.0) 32 (45.1) 101 (49.0) 0.241
1.01 – 2.00 mm 21 (24.7) 9 (18.0) 14 (19.7) 44 (21.3)
2.01 – 4.00 mm 17 (20.0) 8 (16.0) 12 (16.9) 37 (18.0)
≥ 4.01 mm 4 (4.7) 7 (14.0) 13 (18.3) 24 (11.7)
Clark levelc
II 3 (3.8) 1 (2.3) 4 (6.6) 8 (4.4) 0.094
III 25 (31.3) 9 (20.9) 9 (14.8) 43 (23.4)
IV 45 (56.3) 30 (69.8) 36 (59.0) 111 (60.3)
V 7 (8.8) 3 (7.0) 12 (19.7) 22 (12.0)
Ulzerationd
no 49 (60.5) 23 (47.9) 36 (50.7) 108 (54.0) 0.301
yes 32 (39.5) 25 (52.1) 35 (49.3) 92 (46.0)
Mitotic activitye
no 15 (37.5) 4 (16.0) 3 (7.0) 22 (20.4) 0.002*
yes 25 (62.5) 21 (84.0) 40 (93.0) 86 (79.6)
Pathologic features of the primary tumors are indicated according to genotype. The categorical variables were compared with the Chi-square test; the significance
level was adjusted with the Bonferroni correction with p < 0.008 considered significant (*). Mitotic activity was defined as presence of ≥ 1 mitosis per high power
field. aNo data on the histologic subtype for n = 5; bno data on Breslow’s index for n = 6; cno data on Clark level available for n = 28; dulceration unknown for n =
12; emissing data for mitotic activity in primary tumors for n = 104; ALM acral lentiginous melanoma, LMM lentigo maligna melanoma, NM nodular melanoma, SSM
superficial spreading melanoma
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to genotype, BRAF-mutant individuals showed a trend
for longer median OS and relative survival when com-
pared to the NRAS-mutant and WT ones (14.8, 10.2
and 9.3 years, respectively). This difference was statisti-
cally significant for patients with relapse only (p = 0.0463),
but not for the entire cohort (Fig. 3).
Other malignancies were commonly found in NRAS-
mutant patients. To determine if non-melanoma cancers
influenced survival and caused earlier demise particu-
larly in the NRAS cohort, OS and RS were calculated
after exclusion of patients with other malignancies.
Indeed, the 5-year OS rate for the NRAS group in-
creased from 68.2 to 74.2% after exclusion of these
cases, whereas the other two cohorts were less affected.
In contrast, the progression times to loco-regional
relapse and to formation of distant metastases were left
virtually unaltered by this selection (Additional file 3:
Figure S2).
In addition, this survival benefit was not consistent in
multivariate analyses with validated prognostic markers
of melanoma, as the mutational status of neither BRAF
nor NRAS was significantly associated with better OS
Table 4 Patterns of disease progressiona
BRAF n = 87 (100.0) NRAS n = 53 (100.0) Wild type n = 72 (100.0) total n = 212a (100.0) p-value
Local relapse
no 86 (98.9) 49 (92.5) 71 (98.6) 206 (97.2) 0.057
yes 1 (1.2) 4 (7.6) 1 (1.4) 6 (2.8)
Relapse of nodal disease (loco-regional)
no 56 (64.4) 21 (39.6) 43 (59.7) 120 (56.6) 0.013*
yes 31 (35.6) 32 (60.4) 29 (40.3) 92 (43.4)
Distant metastasesb
no 18 (21.2) 6 (12.0) 23 (33.3) 47 (23.0) 0.021
yes 67 (78.8) 44 (88.0) 46 (66.7) 157 (77.0)
The frequency and types of disease progression are displayed according to the genotype. Patients were allowed to have more than one progression type. Statistical analyses
were performed with the Chi-square test; the significance level was adjusted with the Bonferroni correction with p < 0.017 considered significant (*). an = 4 patients had
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Time to distant metastasis (relapse only)
p = 0.1324
Fig. 1 Time from primary diagnosis to first disease progression of any type (a), first loco-regional relapse (b), and first detection of distant metastases
(c). Times to the respective events were calculated with the cumulative incidence function and are indicated in years. The BRAF mutant cohort showed
the longest time to progression with the median time to first nodal relapse not being reached in the observation period (b). In contrast, the
NRAS mutant cohort had the shortest time to nodal relapse (b), while the median time to progression of any type (a) or to the formation of
distant metastases (c) was almost equal in NRAS mutant and WT melanoma patients. Patients who initially presented with stage IV disease (n = 8) were
precluded from the analyses shown in (b) and (c). The right panels of (b) and (c) indicate progression curves after selection for patients with relapse.
The indicated p-values were calculated with the Gray’s test
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(BRAF: HR for death 0.46, 95% CI 0.20 – 1.07; NRAS:
HR for death 0.70, 95% CI 0.33–1.47; Table 6). Instead,
we identified a positive sentinel lymph node status (HR
2.65; 95% CI 1.15–6.10) and treatment with ICB in
stage IV disease (HR 0.17; 95% CI 0.06–0.48) as multi-
variate risk factors.
Discussion
In this study, we assessed genotype-phenotype correla-
tions in 217 patients with melanoma. BRAF mutations
were identified in 40.1% and NRAS mutations in 24.4%,
while no alterations in either gene were found in the
remaining 33.2%. Even though the genotype was not a
risk factor in multivariate analysis, BRAF-mutant melan-
oma patients showed a trend towards better overall and
relative survival. In contrast, NRAS-mutant patients
were more likely to develop early nodal relapse and
metastatic disease than the BRAF-mutant or WT cohort
suggesting that they were at highest risk for disease pro-
gression and ultimately disease-specific mortality.
Regarding characteristics of the primary tumor, trunk
was the most common localization in BRAF-mutant
patients. The primaries of this cohort showed less mitotic
activity than the NRAS and the WT cohorts, in keeping
with a prior study [15]. The nodular subtype was more
common in BRAF- and NRAS-mutant groups, while there
were no major differences regarding other histologic risk
factors such as tumor depth or presence of ulceration.
These results are in line with previous investigations in
which BRAF mutations preferentially occurred in mela-
nomas of skin with little solar elastosis and less commonly
affected the head and neck area [3, 7].
Conversely, NRAS mutations had previously been
associated with higher Breslow’s thickness and fast
growth of the primary tumor [15, 16]. Although this
correlation was not confirmed in our collective, NRAS-
mutant tumors accounted for 4 out of 6 local relapses at
the primary tumor site and loco-regional recurrence and
distant metastasis were significantly more commonly
observed in NRAS-mutant patients. The time to nodal
recurrence was significantly shortest in the NRAS
cohort. These results were further confirmed in a
Table 5 Multivariate risk model for disease progression
Factor HR 95% CI p-value
Age
50 – 59 2.20 1.15 – 4.21 0.017*
60 – 69 1.40 0.68 – 2.89 0.358
≥ 70 1.68 0.79 – 3.59 0.178
Breslow’s index
1.01 – 2.00 mm 0.93 0.48 – 1.80 0.822
2.01 – 4.00 mm 0.65 0.32 – 1.32 0.229
≥ 4.01 mm 1.43 0.65 – 3.15 0.375
Sex
female 1.03 0.61 – 1.72 0.921
Histologic subtype
nodular type 1.29 0.75 – 2.22 0.361
Mutational status
BRAF 0.75 0.39 – 1.46 0.388
NRAS 2.01 1.02 – 3.98 0.045*
SLNB
positive 0.95 0.51 – 1.79 0.877
Multivariate model for disease progression where death was considered a
competing risk (competing risk model). The references for each factor were
age < 50 years, Breslow’s thickness < 1.00 mm, male sex, non-nodular histologic
subtype, WT for BRAF and NRAS, and negative SLNB status. Hazard ratios (HR) for
progression and 95% confidence intervals (CI) are indicated; SLNB sentinel lymph














Survival after first progression (any)
years
















































































Fig. 2 Post-progression survival after first disease progression of any type (a), first nodal relapse (b), and metastatic disease (c). All three genotypes
showed similar Kaplan-Meier curves for survival after any disease progression (a) and loco-regional nodal recurrence (b). Patients who were mutant for
NRAS showed a slightly shorter median survival in stage IV disease (1.8 years) compared to patients with BRAF mutant (2.2 years) and WT (2.5 years)
melanoma. However, this difference was not significant. The indicated p-values were calculated with the log-rank test
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multivariate model for disease progression. Even though
NRAS mutational status was not a significant risk factor
for OS in multivariate analyses, these results imply that
NRAS-mutant tumors appear intrinsically more aggres-
sive and are at high risk for disease progression. This
trend for shorter relapse-free survival was also supported
by other large-scale analyses [12, 15]. However, in stage
IV, the survival differences between NRAS-mutant and
non-NRAS-mutant patients proposed previously were
not statistically significant in our study, even though
NRAS-mutant patients showed a tendency towards
shorter survival when metastatic lesions were detected
[12, 14]. OS defined as time from the first diagnosis of
melanoma to death did not show differences between
the genotypes in multivariate analyses, suggesting that
the impact of NRAS mutations are more evident in ear-
lier disease stages as proposed by Ellerhorst and col-
leagues [16]. After 5 and 10 years, the BRAF cohort
showed a slight survival advantage of 10–15%, yet with-
out significance for the entire cohort. Post-hoc sample
size calculations revealed that at least 1239 patients
would have been necessary to significantly assess such
differences in survival. Thus, our study was likely under-
powered. Nevertheless, these findings raise the question
on whether NRAS-mutant patients should undergo a
more intensive follow-up after primary diagnosis and
whether large trials should stratify for NRAS as inde-
pendent risk factor.
The strengths of this analysis include the reconstruc-
tion of the entire interval from diagnosis of the primary
culprit tumor to death or last follow-up as censoring
event. Based on our data, we conclude that BRAF and
NRAS alterations rather affect early disease stages. Thus,
it is indispensable to analyze the complete course of the
disease and not only focus on stage IV disease where the
differences between the genotypes may be less evident.
Furthermore, we assessed the prognostic significance of
BRAF and NRAS mutations in the presence of novel
therapies such as BRAFi and MEKi or ICB which are
broadly available nowadays and led to significant survival
benefits in phase II and III trials [29, 30]. However, data



























































































































Relative survival (relapse only)d
Fig. 3 OS and relative survival from diagnosis of the culprit melanoma. a + c Kaplan-Meier curves are shown for overall survival according to genotype
for the entire cohort (a) and after selection for patients with relapse (c). BRAF-mutant melanoma patients showed a trend towards longer
survival compared to NRAS-mutant and WT melanoma patients, which was significant in patients with relapse only. The indicated p-value
was calculated with the log-rank test. b + d Relative survival was defined as ratio of the observed survival of the study cohort to the expected survival of
a reference population to adjust for cause- and age-specific mortality. Similar results were observed compared to the Kaplan-Meier curves from (a) and (c)
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proposing that the mutation status is not prognostic in
stage IV disease were conducted either before BRAFi
and MEKi were accessible outside of trials or pre-
cluded patients who were treated with BRAFi and
MEKi [11, 31, 32]. To reflect a real-world situation
available outside of clinical trials, we believe that is im-
portant to take these therapies into consideration.
Our study does have several limitations. First, the co-
hort was sampled based on availability of tissue as well
as of the mutation status, regardless of other demo-
graphic and clinical parameters. Although this approach
was performed in several other sound reports [3, 12, 16],
sampling based on the sole availability of BRAF and
NRAS mutational status may bear potential for bias.
While it minimizes a potential survivorship bias, it may
enrich for patients who underwent surgery or invasive
biopsies in stage III or IV disease to obtain tumor mater-
ial for the mutation analyses. Our collective may not be
representative of the target population, because we in-
cluded patients, in whom molecular testing was clinically
indicated due to disease progression. Indeed, the high
overall relapse rate of 85.8% demonstrates that our
population was skewed towards high-risk melanoma pa-
tients. Thus, our results may not be generalizable to all
melanoma patients and, in particular, may not be valid
for individuals with lower risk disease. To estimate the
effect of this bias, we performed time to event analyses
including patients with relapse only. The time to loco-
regional relapse was less favorable for NRAS-mutant pa-
tients and overall as well as relative survival significantly
more favorable for BRAF-mutant patients after this se-
lection. These data were largely consistent with our
main findings within the entire population. Nevertheless,
we cannot exclude that the lack of inclusion of lower
risk disease potentially reinforces selection bias.
In addition to a potential sampling bias, further
shortcomings of our study include the retrospective
design and low number of patients with rare mutations
of BRAF and NRAS. The mutation BRAF V600K had
previously been associated with older age, head and
neck localization of the primary tumor, shorter distant
metastasis-free and shorter OS compared to V600E
[11, 18, 33]. We identified 15 patients with V600K-
mutant melanoma accounting for 6.9 and 17.2% of the
Table 6 Cox regression analyses of validated risk factors for melanoma
Univariate Multivariate
Factor HR 95% CI p-value HR 95% CI p-value
Age
50 – 59 1.53 0.70 – 3.34 0.285 1.53 0.70 – 3.34 0.285
60 – 69 1.62 0.74 – 3.55 0.230 1.62 0.74 – 3.54 0.230
≥ 70 1.35 0.55 – 3.30 0.507 1.35 0.55 – 3.30 0.507
Breslow’s index
1.01 – 2.00 mm 0.79 0.39 – 1.59 0.502 0.79 0.39 – 1.59 0.502
2.01 – 4.00 mm 0.59 0.27 – 1.29 0.182 0.59 0.27 – 1.29 0.182
≥ 4.01 mm 1.55 0.61 – 3.92 0.356 1.55 0.61–3.92 0.356
Sex
female 1.72 0.98 – 3.06 0.059 1.72 0.98 – 3.06 0.059
Histologic subtype
nodular type 1.29 0.55 – 3.02 0.553 1.29 0.55 – 3.02 0.553
Mutational status
BRAF 0.46 0.20 – 1.07 0.072 0.46 0.20 – 1.07 0.072
NRAS 0.70 0.33 – 1.47 0.346 0.70 0.33 – 1.47 0.346
SLNB
positive 2.65 1.15 – 6.10 0.022* 2.65 1.15 – 6.10 0.022*
Treatment
targeted therapy 1.10 0.49 – 2.46 0.821 1.10 0.49 – 2.46 0.821
ICB 0.17 0.06 – 0.48 0.001*** 0.17 0.06 – 0.48 0.001***
chemotherapy 0.57 0.25 – 1.29 0.175 0.57 0.25 – 1.29 0.175
Univariate and multivariate analysis on survival from the primary diagnosis (OS) of melanoma. Validated risk factors, the mutational status, and therapies were
assessed with Cox proportional hazard regression. The references for each factor were age < 50 years, male sex, Breslow’s thickness < 1.00 mm, negative SLNB
status, WT for BRAF and NRAS, non-nodular subtype, and no systemic therapy. Hazard ratios (HR) for death and 95% confidence intervals (CI) are indicated; SLNB
sentinel lymph node biopsy, ICB immune checkpoint blockade; *p < 0.05, ***p < 0.001
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entire and BRAF-mutant population, respectively. This
proportion is somewhat lower than reported before and
precluded further subgroup analyses due to the small
number of cases. Non-V600 mutations of BRAF were re-
ported in 7 (3.2%) patients in our study, two of whom had
a concomitant mutation in NRAS. More specifically, the
mutations K601E and L597S were identified in 5 (2.3%)
patients. The small number limited further statistical ana-
lyses and conclusions on this particular subpopulation.
Others have provided evidence that the alterations K601E
and L597 show distinct clinicopathologic features from
general V600E/K mutations. The so far largest series on
these mutations suggested that tumors harboring K601E
mutations are rather similar to tumors with V600E muta-
tions, whereas those with L597 mutations were akin to
BRAF WT tumors [34]. However, data regarding treat-
ment responses to BRAFi and the clinical prognosis is
sparse due to the paucity of these mutations and exclusion
from major trials [34, 35].
Conclusions
We provide important insights into the significance of
BRAF and NRAS mutations in a real-world setting when
BRAFi, MEKi, and ICB were largely available. NRAS-
mutant melanoma patients showed a significantly higher
portion of nodal relapse and the shortest time to loco-
regional nodal relapse. Positive SLNB was a significant
risk factor and treatment with ICB in stage IV a signifi-
cant protective factor for OS in multivariate analysis.
Even though the mutational status was not a consistent
risk factor for OS in multivariate analysis, our results
suggest that NRAS-mutant tumors tend to behave more
aggressively than their BRAF-mutant and WT counter-
parts in a high-risk melanoma population.
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